Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Amgen China today announced that XGEVA® (denosumab) Injection has been approved by the National Medical Products Administration (NMPA) for the treatment of adults and skeletally mature adolescents (defined as having at least one mature long bone and weigh≥45 kg) with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity.

Xgeva is a RANK ligand (RANKL) inhibitor indicated for...Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or here surgical resection is likely to result in severe morbidity.

Denosumab is standard treatment in unresectable or metastatic GCT…

Giant Cell tumor of bone…Preferred Regimens…Denosumab. For patients with lesions that are resectable with unacceptable morbidity or unresectable axial lesions, the guidelines have included denosumab and/or serial embolizations as preferred options.